SpyGlass Pharma, Inc. (SGP)
26.03
-0.39
(-1.48%)
USD |
NASDAQ |
Aug 31, 14:09
SpyGlass Pharma Enterprise Value : 651.10M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 651.10M |
| August 27, 2026 | 668.15M |
| August 26, 2026 | 658.46M |
| August 25, 2026 | 657.12M |
| August 24, 2026 | 645.75M |
| August 21, 2026 | 654.11M |
| August 20, 2026 | 644.74M |
| August 19, 2026 | 678.19M |
| August 18, 2026 | 631.70M |
| August 17, 2026 | 629.69M |
| August 14, 2026 | 643.74M |
| August 13, 2026 | 609.29M |
| August 12, 2026 | 612.63M |
| August 11, 2026 | 598.59M |
| August 10, 2026 | 608.95M |
| August 07, 2026 | 613.97M |
| August 06, 2026 | 595.24M |
| August 05, 2026 | 559.45M |
| August 04, 2026 | 573.84M |
| August 03, 2026 | 526.01M |
| July 31, 2026 | 520.99M |
| July 30, 2026 | 527.35M |
| July 29, 2026 | 500.25M |
| July 28, 2026 | 490.56M |
| July 27, 2026 | 463.80M |
| Date | Value |
|---|---|
| July 24, 2026 | 452.76M |
| July 23, 2026 | 465.80M |
| July 22, 2026 | 454.43M |
| July 21, 2026 | 445.40M |
| July 20, 2026 | 437.04M |
| July 17, 2026 | 428.68M |
| July 16, 2026 | 461.79M |
| July 15, 2026 | 456.44M |
| July 14, 2026 | 436.04M |
| July 13, 2026 | 433.03M |
| July 10, 2026 | 520.66M |
| July 09, 2026 | 438.71M |
| July 08, 2026 | 451.76M |
| July 07, 2026 | 420.32M |
| July 06, 2026 | 405.94M |
| July 02, 2026 | 407.94M |
| July 01, 2026 | 418.65M |
| June 30, 2026 | 511.96M |
| June 29, 2026 | 474.42M |
| June 26, 2026 | 458.71M |
| June 25, 2026 | 379.47M |
| June 24, 2026 | 404.21M |
| June 23, 2026 | 408.22M |
| June 22, 2026 | 397.19M |
| June 18, 2026 | 375.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.908B |
| Corcept Therapeutics, Inc. | 11.99B |
| Veru, Inc. | 21.65M |
| Johnson & Johnson | 673.78B |
| Eli Lilly & Co. | 1.152T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.86M |
| Total Expenses (Quarterly) | 19.86M |
| EPS Diluted (Quarterly) | -0.5939 |
| Earnings Yield | -7.39% |
| Normalized Earnings Yield | -7.385 |